JP2011511804A - 疾患マーカーおよびその使用 - Google Patents

疾患マーカーおよびその使用 Download PDF

Info

Publication number
JP2011511804A
JP2011511804A JP2010546054A JP2010546054A JP2011511804A JP 2011511804 A JP2011511804 A JP 2011511804A JP 2010546054 A JP2010546054 A JP 2010546054A JP 2010546054 A JP2010546054 A JP 2010546054A JP 2011511804 A JP2011511804 A JP 2011511804A
Authority
JP
Japan
Prior art keywords
ifnα
expression
activity
profile
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010546054A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011511804A5 (enExample
Inventor
ヤオ,イーホン
モアハウス,クリス
ヒグス,ブランドン
ジャラル,バヒジャ
グリーンバーグ,スティーブン,エー.
Original Assignee
メディミューン,エルエルシー
ブライアム アンド ウィメンズ ホスピタル,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン,エルエルシー, ブライアム アンド ウィメンズ ホスピタル,インコーポレーテッド filed Critical メディミューン,エルエルシー
Publication of JP2011511804A publication Critical patent/JP2011511804A/ja
Publication of JP2011511804A5 publication Critical patent/JP2011511804A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2010546054A 2008-02-08 2009-02-06 疾患マーカーおよびその使用 Pending JP2011511804A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US696308P 2008-02-08 2008-02-08
PCT/US2009/033407 WO2009100342A2 (en) 2008-02-08 2009-02-06 Disease markers and uses thereof

Publications (2)

Publication Number Publication Date
JP2011511804A true JP2011511804A (ja) 2011-04-14
JP2011511804A5 JP2011511804A5 (enExample) 2012-03-15

Family

ID=40952717

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010546054A Pending JP2011511804A (ja) 2008-02-08 2009-02-06 疾患マーカーおよびその使用

Country Status (12)

Country Link
US (1) US20110262928A1 (enExample)
EP (2) EP2848702A1 (enExample)
JP (1) JP2011511804A (enExample)
KR (1) KR20110005783A (enExample)
CN (1) CN101999001B (enExample)
AU (1) AU2009212216B2 (enExample)
BR (1) BRPI0908065A2 (enExample)
CA (1) CA2714410A1 (enExample)
ES (1) ES2529593T3 (enExample)
MX (1) MX2010008698A (enExample)
SG (1) SG188147A1 (enExample)
WO (1) WO2009100342A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012522508A (ja) * 2009-03-31 2012-09-27 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ シェーグレン症候群の診断および治療のためのバイオマーカーとしての示差的に発現されるマイクロrna
JP2016153736A (ja) * 2015-02-20 2016-08-25 一三 西野 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法
JP2016526888A (ja) * 2013-06-28 2016-09-08 アキュメン リサーチ ラボラトリーズ プライヴェット リミテッドAcumen Research Laboratories Pte. Ltd. 敗血症バイオマーカー及びそれらの使用
JP2022550439A (ja) * 2019-10-04 2022-12-01 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン 乾癬治療における抗腫瘍壊死因子療法に対する応答性を判定するための方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2542836T3 (es) * 2007-07-12 2015-08-12 The Brigham And Women's Hospital, Inc. Composiciones y métodos para diagnosticar y evaluar miopatías inflamatorias
CA2878025C (en) 2008-01-18 2018-12-11 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
ES2613055T3 (es) * 2009-09-03 2017-05-22 Medimmune, Llc Diagnóstico de interferón de tipo 1
WO2011126105A1 (ja) * 2010-04-08 2011-10-13 三菱化学メディエンス株式会社 免疫系の異常疾患または関節系の異常疾患への罹患またはこれらの病勢を判定するための検査方法
MX2013000917A (es) 2010-07-23 2013-07-05 Harvard College Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
KR20130041961A (ko) 2010-07-23 2013-04-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액에서 질환 또는 상태의 특징을 검출하는 방법
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
WO2012012717A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
US20140274789A1 (en) * 2011-08-11 2014-09-18 Andreas Keller Complex sets of mirnas as non-invasive biomarkers for psoriasis
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
EP2653554A1 (en) * 2012-04-17 2013-10-23 Istituto Nazionale Di Genetica Molecolare-INGM Immune response biomarkers
EP2965077B1 (en) 2013-03-09 2022-07-13 Harry Stylli Methods of detecting cancer
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
EP4428251A3 (en) 2014-09-11 2024-12-18 Immunis.AI, Inc. Methods of detecting prostate cancer
CN108379584B (zh) * 2018-04-12 2020-08-11 上海交复生物医药科技有限公司 RSAD2通过wnt通路影响肿瘤细胞替莫唑胺耐药性
US20210361744A1 (en) * 2018-04-27 2021-11-25 Stemline Therapeutics, Inc. Methods of Treating an Autoimmune Disease with a Human Interleukin-3 (IL-3)-Diphtheria Toxin Conjugate (DT-IL3)
CN110085282A (zh) * 2019-04-23 2019-08-02 华中师范大学 核酸结构中核苷酸与核苷酸相互作用预测的方法
CN110108880A (zh) * 2019-05-30 2019-08-09 四川大学华西医院 Fez1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CN110161235B (zh) * 2019-06-26 2022-04-12 江苏省中医院 三种血清蛋白联合用于强直性脊柱炎诊断的用途
CN111378742A (zh) * 2020-04-16 2020-07-07 嘉兴程瑞医药科技有限公司 microRNA生物标志物及其在制备自身免疫疾病检测试剂盒中的应用
CN113388677A (zh) * 2021-06-17 2021-09-14 河北医科大学第二医院 包括ifi44的干燥症诊断标志物组合

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019219A2 (en) * 2005-08-05 2007-02-15 Genentech, Inc. Methods and compositions for detecting autoimmune disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
EP0139676B1 (en) 1983-02-04 1992-11-25 Cytoclonal Pharmaceutics Inc. Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
DE3306060A1 (de) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US20070166281A1 (en) * 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
US7833795B2 (en) * 2004-08-24 2010-11-16 The Trustees Of The University Of Pennsylvania Assessment of cardiovascular risk using isoprostane biomarkers and COX-2 selective inhibitors
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
WO2008070135A2 (en) * 2006-12-06 2008-06-12 Medimmune, Llc. Methods of treating systemic lupus erythematosus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019219A2 (en) * 2005-08-05 2007-02-15 Genentech, Inc. Methods and compositions for detecting autoimmune disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012036649; Expert opinion on investigational drugs 15, 6, 200606, p.721-727 *
JPN6013045746; Arthritis Rheum. (2007) vol.56, no.11, p.3784-3792 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012522508A (ja) * 2009-03-31 2012-09-27 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ シェーグレン症候群の診断および治療のためのバイオマーカーとしての示差的に発現されるマイクロrna
JP2016526888A (ja) * 2013-06-28 2016-09-08 アキュメン リサーチ ラボラトリーズ プライヴェット リミテッドAcumen Research Laboratories Pte. Ltd. 敗血症バイオマーカー及びそれらの使用
JP2016153736A (ja) * 2015-02-20 2016-08-25 一三 西野 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法
JP2022550439A (ja) * 2019-10-04 2022-12-01 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン 乾癬治療における抗腫瘍壊死因子療法に対する応答性を判定するための方法

Also Published As

Publication number Publication date
BRPI0908065A2 (pt) 2015-08-11
EP2252703A2 (en) 2010-11-24
WO2009100342A2 (en) 2009-08-13
CA2714410A1 (en) 2009-08-13
HK1150063A1 (en) 2011-10-28
CN101999001B (zh) 2013-11-20
EP2848702A1 (en) 2015-03-18
KR20110005783A (ko) 2011-01-19
EP2252703A4 (en) 2011-12-21
AU2009212216A1 (en) 2009-08-13
WO2009100342A3 (en) 2009-12-30
SG188147A1 (en) 2013-03-28
EP2252703B1 (en) 2014-11-05
CN101999001A (zh) 2011-03-30
ES2529593T3 (es) 2015-02-23
AU2009212216B2 (en) 2015-04-09
US20110262928A1 (en) 2011-10-27
MX2010008698A (es) 2010-12-20

Similar Documents

Publication Publication Date Title
JP2011511804A (ja) 疾患マーカーおよびその使用
JP5411129B2 (ja) インターフェロンα誘導性薬力学的マーカー
AU2007327995B2 (en) Interferon alpha-induced pharmacodynamic markers
AU2010289383B2 (en) Type 1 interferon diagnostic
CN101594882A (zh) 干扰素α诱导的药代动力学标记物
US20110287022A1 (en) Interferon alpha-induced pharmacodynamic markers
US20100261172A1 (en) Interferon alpha-induced pharmacodynamic markers
WO2009155559A1 (en) Interferon alpha-induced pharmacodynamic markers
AU2015203772A1 (en) Disease markers and uses thereof
HK1150063B (en) Disease markers and uses thereof
HK1140406A (en) Interferon alpha-induced pharmacodynamic markers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140805